AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
14. November 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein...
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
13. November 2024 07:00 ET
|
AC Immune SA
AC Immune to Present at the Jefferies 2024 London Healthcare Conference Lausanne, Switzerland, November 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
05. November 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and...
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
17. September 2024 07:00 ET
|
AC Immune SA
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease Prescreening rate of Phase 2b ReTain trial triggers clinical...
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
28. August 2024 09:00 ET
|
AC Immune SA
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s...
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
06. August 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront...
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
31. Juli 2024 08:30 ET
|
AC Immune SA
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small...
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
25. Juli 2024 07:00 ET
|
AC Immune SA
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical AD expected this quarterPhase 2b ReTain...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
16. Juli 2024 07:00 ET
|
AC Immune SA
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s...
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
28. Mai 2024 07:00 ET
|
AC Immune SA
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company...